Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMF-219 in Healthy Adults and Adults With T2D
NCT05731544Phase 2Completed
- Sponsor
- Biomea Fusion
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Covalent Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of icovamenib in type 2 diabetes mellitus (T2DM), sponsored by Biomea Fusion. Started Aug 2022; status: completed.
02
Drugs
icovamenib
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05731544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731544.